TrialEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Trial details
- Registry ID
- NCT06463665
- Phase
- Phase 2
Drug research
Olvimulogene nanivacirepvec
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as GL-ONC; GLV-1h68; Olvi-Vec
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerNCT06463665 | Genelux Corporation | Phase 2 | Recruiting | 2027-02Estimated |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |